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Background: The prevalence of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) has increased
recently. The aim of this study was to further characterise and to assess the occurrence of ESBL-EC in Riyadh, to use
pulsed field gel electrophoresis (PFGE) typing to investigate the epidemiology of ESBL-EC and to determine the
prevalence of ST131 in ESBL-EC.
Methods: A total of 152 E. coli isolates were collected at a tertiary hospital in Riyadh from September 2010 to June
2011. Genotypic and phenotypic methods were used to characterise ESBLs. PFGE was used to determine genetic
relatedness. Detection of ST131 and CTX-M-like ESBLs was performed using real-time PCR.
Results: Of 152 strains, 31 were positive for ESBLs by phenotypic methods. The blaCTX-M-15 gene was highly
prevalent (30/31 strains, 96.77%) among the 31 ESBL-positive E. coli strains. The blaCTX-M-27 gene was detected in
one strain. Twenty (64.5%) out of 31 of ESBL-EC were ST131. PFGE revealed 29 different pulsotypes.
Conclusions: Our study documented the high prevalence of ESBLs in E. coli isolates, with CTX-M-15 as the predominant
ESBL gene. ST131 clone producing CTX-M-15 has a major presence in our hospital. The high prevalence of CTX-M
producers was not due to the spread of a single clone. To the best of our knowledge, this study represents the first
report of CTX-M-15 and CTX-M-27 β-lactamases and the detection of the ST131 clone in Saudi E. coli isolates.
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Extended-spectrum β-lactamase-producing Escherichia
coli (ESBL-EC) pose a serious threat to the successful
treatment of common bacterial infections. Over the past
two decades, there has been an increase in the preva-
lence of ESBL-EC [1]. In addition to TEM and SHV vari-
ants of ESBLs, CTX-M enzymes have replaced TEM and
SHV in the past several years. CTX-M β-lactamases have
emerged as the predominant ESBL type worldwide [2].
Within the CTX-M family, CTX-M-15 is currently the
most widely disseminated CTX-M genotype [2,3]. Re-
cently, several studies have highlighted the worldwide* Correspondence: malagamy@ksu.edu.sa
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stated.spread of the E. coli ST131 clone [4-6]. The successful dis-
semination of CTX-M-15 has been considered to be due
to the dissemination of genetic elements and the clonal
expansion of a pandemic E. coli clone, ST131, with high
virulence potential [7]. The E. coli ST131 clone has been
reported worldwide; this clone is frequently multidrug-
resistant and commonly carries CTX-M-15 [6,8].
Previously published studies in Saudi Arabia have
sought to determine the prevalence of ESBL-producing
isolates, mainly Klebsiella pneumoniae and, to a lesser
extent, E. coli, with CTX-M-15 being the most common
ESBL [9-17]. However, there is a paucity of studies on
the prevalence of ESBL-EC from Saudi Arabia. Until
now, no detailed reports characterizing the genotypes of
ESBL enzymes or the spread of the ST131 clone in
ESBL-EC out of Saudi Arabia have been published.
Therefore, this study was performed to investigate theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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clinical ESBL-EC isolates obtained from a tertiary hos-
pital in Riyadh, Saudi Arabia.
Materials and methods
Bacterial isolates
One hundred fifty-two non-consecutive, non-duplicate
clinical E. coli isolates were obtained from inpatients
hospitalised at a tertiary hospital in Riyadh, Saudi Arabia.
These isolates were collected over a period of 10 months
from September 2010 to June 2011. The samples con-
tained 119 isolates from urine, 11 from sputum, 10 from
stool, 9 from blood, and 3 from abscesses. Isolates were
identified using traditional bacteriological methods and
biochemical testing with an API 20E according to the
manufacturer’s recommendations. The isolates were
stored at −80°C in 15% glycerol (v/v) in tryptic soy broth.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed using
the disc diffusion method of the Clinical and Laboratory
Standards Institute (CLSI) with discs from BBL (Becton
Dickinson, Sparks Glencoe, MD, USA). The minimum
inhibitory concentration (MIC) for each antibiotic was
determined using the dilution and diffusion method on
Mueller–Hinton agar with E-test strips (bioMerieux,
Marcy L’Etoile, France). The results were interpreted ac-
cording to the current guidelines of the CLSI [18]. The
following antibiotics were tested: amikacin, amoxicillin,
amoxicillin–clavulanate, aztreonam, cefepime, cefotax-
ime, cefoxitin, ceftazidime, ceftazidime/clavulanate, cip-
rofloxacin, colistin, fosfomycin, gentamicin, imipenem,
meropenem, piperacillin, piperacillin–tazobactam, and
tigecycline. E. coli ATCC 25922 was used for quality
control.
Phenotypic detection of ESBL production
ESBL production was detected using the 2011 CLSI rec-
ommendations for ESBL screening and confirmation
tests [18]. The double-disc synergy test and ESBL strip E-
tests (bioMerieux, Marcy L’Etoile, France) were performed
for the detection and confirmation of ESBLs, respectively.
For the double-disc synergy test, a ceftazidime disc (30 μg)
was placed 20 mm away from a disc containing ceftazi-
dime–clavulanate (30/10 μg). When the inhibition zone
between at least one of the combination discs and its cor-
responding single antibiotic disc differed by ≥ 5 mm, the
strain was identified as an ESBL producer. For the E-test,
an ESBL strip containing ceftazidime and ceftazidime–cla-
vulanate was used to determine the MIC ratio according
to the manufacturer's instructions. E. coli ATCC 25922
(negative control) and K. pneumoniae ATCC 700603
(positive control) were used as reference strains.PCR of β-lactamases
Polymerase chain reaction (PCR) and sequence analyses
were conducted to determine the gene responsible for
the ESBL phenotype in the ESBL producers. PCR for
blaTEM, blaSHV, and blaCTX-M genes were conducted
using PCR primers and conditions that have been previ-
ously described [19]. The five CTX-M subgroups (CTX-
M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25)
were amplified using PCR primers and procedures as
previously described [20].
Detection of blaCTX-M-15-like genes was performed
using real-time PCR according to previously published
methods [6]. Primers were used to amplify a 49-bp re-
gion that is conserved amongst group 1 CTX-M genes
as follows: MC-3-15 F (5′-TGG GGG ATA AAA CCG
GCA G-3′) and MC-3-15R (5′-GCG ATA TCG TTG
GTG GTG C-3′). Briefly, a 25-μL reaction mixture con-
tained final concentrations of 1× SYBR Green PCR Master
Mix buffer (Applied Biosystems, CA, USA), 0.3 μM of
each forward and reverse primers, 100 ng of DNA, and
RNase/DNase-free water. The reaction was performed in
an ABI 96-Well Optical Reaction Plate. The thermal cyc-
ling conditions were: initial denaturation at 95°C for
10 min, followed by 25 cycles at 95°C for 15 sec and 68°C
for 45 sec. Following amplification, melting curve analysis
was performed by heating the PCR product from 55°C to
95°C with a ramp rate of 0.05°C/s to verify the presence of
a specific product according to its specific melting
temperature. The results were analysed using the melting
curve analysis software from Applied Biosystems.
DNA sequencing
Automatic sequencing was performed on both strands
of all PCR products using the ABI Prism 3700 DNA Se-
quencer (Applied Biosystems, Foster City, CA). The
types of β-lactamase genes were identified by comparison
with the sequences in the database of G. Jacoby and K.
Bush (http://www.lahey.org/Studies/) and the sequences
in GenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) of chromosomal
DNA digested with XbaI (New England BioLabs, MA,
USA) was performed according to a standard protocol
[21]. Electrophoresis of the prepared samples was per-
formed on the CHEF-DRIII system (Bio-Rad Laborator-
ies) with 3 litres of 0.5X TBE running buffer. The gels
were run with an initial switch time of 2.2 sec, a final
switch time of 54.2 sec, a run time of 22 hours, an angle
of 120°, a gradient of 6.0 V/cm, and a temperature of 14°C.
Lambda ladder (New England BioLabs) was used as a mo-
lecular weight marker. Each gel was stained with 1 μg/ml
ethidium bromide for 30 minutes and destained with dis-
tilled water for 30 minutes. The gels were photographed
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lysed using BioNumerics Software (Applied Maths, Keistraat
sint-Martens-laten, Belgium). Cluster analysis was per-
formed based on the Dice coefficient with a 1.8% band tol-
erance and an optimisation of 4% for comparisons of
DNA profiles. A similarity coefficient of 80% was applied
to the generated dendrogram, which corresponds to the
criteria of Tenover et al. [22].
Detection of the ST131 clone
ST131 clone detection was performed using real-time
PCR according to previously published methods [6]. The
following primers were used to detect the ST131clone:
ST131TF (5′-GGT GCT CCA GCA GGT G-3′) with
ST131TR (5′-TGG GCG AAT GTC TGC-3′), and
ST131AF (5′-GGC AAT CCA ATA TGA CCC-3′) with
ST131AR (5′-ACC TGG CGA AAT TTT TCG-3′). The
thermal cycling conditions for the ST131 assays included
an initial denaturation at 95°C for 10 min followed by 40
cycles at 95°C for 15 sec and 60°C for 1 min. Reaction
conditions and melt curve analyses were carried out as de-
scribed above.
Results
Antimicrobial susceptibility and ESBL prevalence
Antimicrobial susceptibility testing results are shown in
Table 1. Imipenem, meropenem, colistin, tigecycline, and
fosfomycin were the most active agents (susceptibility:
100%). Out of the 152 strains, 50% were resistant toTable 1 Resistance rates for clinical Escherichia coli







Amoxicillin 31 (100) 121 (100) 152 (100)
Amoxicillin/clavulanic acid 31 (100) 115 (95) 146 (96)
Piperacillin 31 (100) 99 (81.81) 130 (85.52)
Piperacillin/tazobactam 24 (77.44) 52 (42.97) 76 (50)
Cefoxitin 22(70.3) 87 (71.1) 109 (71.7)
Ceftazidime 31 (100) 2 (1.65) 33 (21.71)
Cefotaxime 31 (100) 3 (2.47) 34 (22.36)
Cefepime 31 (100) 2 (1.65) 33 (21.71)
Aztreonam 31 (100) 2 (1.65) 33 (21.71)
Imipenem 0 (0.0) 0 (0.0) 0 (0.0)
Meropenem 0 (0.0) 0 (0.0) 0 (0.0)
Ciprofloxacin 30 (96.77) 49 (40.5) 79 (51.97)
Gentamicin 26 (83.87) 37 (30.58) 63 (41.44)
Amikacin 17 (54.38) 25 (20.66) 42 (27.63)
Colistin 0 (0.0) 0 (0.0) 0 (0.0)
Tigecycline 0 (0.0) 0 (0.0) 0 (0.0)
Fosfomycin 0 (0.0) 0 (0.0) 0 (0.0)piperacillin/tazobactam, 51.97% to ciprofloxacin, and
41.44% to gentamicin. The resistance rates for cefotaxime,
aztreonam, cefepime, and amikacin were 22.36%, 21.71%,
21.71%, and 27.63%, respectively. Over 96%, 85.5% and
71.7% of the isolates were non-susceptible to amoxicillin/
clavulanic acid, piperacillin and cefoxitin, respectively.
Of the 152 E. coli isolates, 31 (20.4%) were confirmed
to be ESBL producers. Of the 119 uropathogenic E. coli
isolates, 11 isolates were from sputum, 10 were from
stool, 9 were from blood, and three were from abscesses;
24 (20.16%), 2 (18.2%), 1 (10%), 3 (33.33%), and 1 (50%)
produced ESBLs, respectively.
The susceptibility and MIC data for the ESBL-EC are
summarised in Tables 1 and 2. Of all 31 isolates identified
as ESBL producers, 30 isolates (96.77%) were resistant to
ciprofloxacin, 17 (54.38%) to amikacin, 26 (83.87%) to
gentamicin, 24 (77.44%) to piperacillin-tazobactam and 22
(70.3%) to cefoxitin. The tested strains were all susceptible
to imipenem, meropenem, colistin, tigecyclin and fosfo-
mycin, and all of them were non-susceptible to amoxicil-
lin, amoxicillin/clavulanic acid, piperacillin, ceftazidime,
cefotaxime, cefepime, and aztreonam.
β-lactamases of ESBL-producing E. coli
Of the 31 E. coli isolates with ESBL phenotypes, all tested
positive for ESBL production. All ESBL types belonged to
the CTX-M family; TEM- or SHV-type ESBL genes were
not detected. Of the 31 ESBL-EC isolates, 30 (96.77%)
produced CTX-M-15, and one (3.23%) produced CTX-M-
27, a variant of CTX-M-14. Another β-lactamase, TEM-1,
was concomitantly produced by 100% of all ESBL-EC iso-
lates (Table 2).
Pulsed-field gel electrophoresis
PFGE was performed on 31 ESBL-EC isolates. Using a
> 80% similarity cut-off point, PFGE analysis showed gen-
etic heterogeneity in the CTX-M-producing E. coli isolates,
revealing 29 distinctive pulsotypes (Figure 1). Twenty-
seven of 29 pulsotypes comprised 87.1% of the isolates.
Each pulsotype contained one strain, except for two pulso-
types, A1 and L1, which contained two strains each. Two
pulsotypes represented 12.9% of all studied ESBL-EC iso-
lates. The results of PFGE revealed that there were no out-
breaks or spreading of one single pulsotype in the hospital.
Prevalence of ST131 in ESBL-EC
Twenty (64.5%) of 31 ESBL-EC isolates were identified
as the ST131 clone. The ST131 ESBL-ES isolates
belonged to 18 different pulsotypes. All ST131 isolates
produced CTX-M-15. Sixteen (66.6) of 24 uropathogenic
ESBL-EC isolates were ST131, while two (66.6%) of three
blood isolates were ST131, one (50%) of two ESBL-EC
isolated from sputum was ST131, and one (100%) ESBL-
EC isolated from a wound was ST131.
Table 2 Clinical specimens, MICs, PFGE, ST131 positivity, and β-lactamase genes among ESBL-producing E. coli isolates
No Isolate Specimen MIC (μg/ml) Pulsotype ST131 β-lactamases
AMC PIP PTZ CT FOX CAZ CAZ/C FP IP MER ATM GM AMK CIP TIG COL FOS
1 EC22 Urine >256 192 32 >256 2 48 32 >256 ≤0.25 ≤0.25 >256 >256 16 >32 ≤0.25 ≤0.5 ≤0.25 A1 + TEM-1 + CTX-M-15
2 EC30 Urine >256 >256 >64 >256 0.5 64 32 >256 ≤0.25 ≤0.25 >256 >256 32 >32 ≤0.25 ≤0.5 ≤0.25 A1 + TEM-1 + CTX-M-15
3 EC11 Urine >256 192 48 >256 0.5 48 >32 >256 ≤0.25 ≤0.25 >256 >256 32 >32 ≤0.25 ≤0.5 ≤0.25 A2 + TEM-1 + CTX-M-15
4 EC27 Urine 192 128 6 >256 16 >256 >32 >256 ≤0.25 ≤0.25 192 >256 6 24 ≤0.25 ≤0.5 ≤0.25 B + TEM-1 + CTX-M-15
5 EC8 Urine >256 >256 8 >256 12 >256 16 >256 ≤0.25 ≤0.25 >256 >256 >256 >32 ≤0.25 ≤0.5 ≤0.25 C - TEM-1 + CTX-M-15
6 EC10 Urine >256 >256 >64 >256 0.25 >256 >32 >256 ≤0.25 0.5 >256 >256 6 >32 ≤0.25 ≤0.5 ≤0.25 D + TEM-1 + CTX-M-15
7 EC1 Urine >256 >256 8 >256 32 >256 16 >256 ≤0.25 ≤0.25 >256 >256 16 >32 ≤0.25 ≤0.5 ≤0.25 E1 - TEM-1 + CTX-M-15
8 EC6 Urine >256 >256 12 >256 24 >256 8 >256 ≤0.25 ≤0.25 >256 >256 2 >32 ≤0.25 ≤0.5 ≤0.25 E2 + TEM-1 + CTX-M-15
9 EC12 Blood >256 >256 12 >256 32 >256 8 >256 ≤0.25 ≤0.25 >256 64 4 4 ≤0.25 ≤0.5 ≤0.25 E3 + TEM-1 + CTX-M-15
10 EC9 Sputum >256 >256 >64 >256 32 >256 8 >256 ≤0.25 ≤0.25 96 >256 6 >32 ≤0.25 ≤0.5 ≤0.25 F - TEM-1 + CTX-M-15
11 EC31 Urine >256 >256 >64 >256 16 >256 8 >256 ≤0.25 ≤0.25 >256 >256 4 2 ≤0.25 ≤0.5 ≤0.25 G + TEM-1 + CTX-M-15
12 EC14 Urine >256 >256 >64 >256 48 >256 32 >256 ≤0.25 1 >256 >256 8 >32 ≤0.25 ≤0.5 ≤0.25 H + TEM-1 + CTX-M-15
13 EC5 Urine >256 >256 >64 >256 16 >256 32 >256 ≤0.25 ≤0.25 >256 >256 2 >32 ≤0.25 ≤0.5 ≤0.25 I1 + TEM-1 + CTX-M-15
14 EC32 Urine >256 >256 >64 >256 24 128 16 >256 ≤0.25 ≤0.25 >256 96 2 >32 ≤0.25 ≤0.5 ≤0.25 I2 + TEM-1 + CTX-M-15
15 EC18 Blood >256 >256 >64 4 32 16 2 24 ≤0.25 ≤0.25 48 >256 16 >32 ≤0.25 ≤0.5 ≤0.25 J1 - TEM-1 + CTX-M-15
16 EC20 Sputum >256 >256 >64 >256 32 >256 >32 >256 ≤0.25 ≤0.25 >256 >256 48 >32 ≤0.25 ≤0.5 ≤0.25 J2 + TEM-1 + CTX-M-15
17 EC2 Urine >256 >256 >64 >256 16 96 8 >256 ≤0.25 ≤0.25 >256 >256 4 >32 ≤0.25 ≤0.5 ≤0.25 J3 + TEM-1 + CTX-M-15
18 EC3 Urine >256 >256 >64 >256 32 24 8 >256 ≤0.25 ≤0.25 >256 >256 8 >32 ≤0.25 ≤0.5 ≤0.25 J4 - TEM-1 + CTX-M-15
19 EC13 Urine >256 >256 >64 >256 32 >256 32 >256 ≤0.25 ≤0.25 >256 >256 32 8 ≤0.25 ≤0.5 ≤0.25 K1 - TEM-1 + CTX-M-15
20 EC33 Urine >256 >256 >64 >256 96 >256 16 >256 ≤0.25 ≤0.25 >256 192 64 12 ≤0.25 ≤0.5 ≤0.25 K2 + TEM-1 + CTX-M-15
21 EC16 Urine >256 >256 >64 >256 24 >256 8 >256 ≤0.25 ≤0.25 >256 >256 64 8 ≤0.25 ≤0.5 ≤0.25 K3 - TEM-1 + CTX-M-15
22 EC4 Urine >256 >256 >64 >256 0.25 192 16 >256 0.5 1.5 >256 4 2 >32 ≤0.25 ≤0.5 ≤0.25 L1 + TEM-1 + CTX-M-15
23 EC15 Urine >256 >256 >64 >256 0.5 >256 18 >256 ≤0.25 ≤0.25 >256 4 0.5 >32 ≤0.25 ≤0.5 ≤0.25 L1 + TEM-1 + CTX-M-15
24 EC25 Urine >256 >256 >64 >256 0.25 12 32 >256 ≤0.25 ≤0.25 >256 3 2 >32 ≤0.25 ≤0.5 ≤0.25 L2 - TEM-1 + CTX-M-15
25 EC26 Urine >256 >256 >64 >256 192 >256 >32 >256 ≤0.25 ≤0.25 >256 >256 2 >32 ≤0.25 ≤0.5 ≤0.25 M1 + TEM-1 + CTX-M-15
26 EC29 Wound swab >256 >256 >64 >256 0.25 >256 8 >256 ≤0.25 ≤0.25 >256 >256 6 >32 ≤0.25 ≤0.5 ≤0.25 M2 + TEM-1 + CTX-M-15
27 EC7 Blood >256 >256 >64 >256 0.25 >256 8 >256 ≤0.25 ≤0.25 >256 2 96 1 ≤0.25 ≤0.5 ≤0.25 N - TEM-1 + CTX-M-27
28 EC19 Stool >256 >256 >64 >256 32 3 32 >256 ≤0.25 ≤0.25 >256 >256 128 >32 ≤0.25 ≤0.5 ≤0.25 O - TEM-1 + CTX-M-15
29 EC21 Urine 128 64 8 >256 128 96 32 >256 ≤0.25 ≤0.25 >256 >256 >256 >32 ≤0.25 ≤0.5 ≤0.25 P + TEM-1 + CTX-M-15
30 EC23 Urine >256 192 32 >256 48 24 32 >256 ≤0.25 ≤0.25 >256 >256 128 >32 ≤0.25 ≤0.5 ≤0.25 Q - TEM-1 + CTX-M-15
31 EC28 Urine >256 >256 8 >256 32 4 16 >256 ≤0.25 ≤0.25 >256 4 2 >32 ≤0.25 ≤0.5 ≤0.25 R + TEM-1 + CTX-M-15
Abbreviations: AMK Amikacin, AMC Amoxicillin/Clavulanic acid, AZT Aztreonam, FP Cefepime, FOX Cefoxitin, CAZ Ceftazidime, CT Cefotaxime, CIP Ciprofloxacin, Clav Clavulanic acid, COL Colistin, GM Gentamicin, IP Imipenem,


























Figure 1 Dendrogram of PFGE patterns showing the genetic relatedness of ESBL-producing E. coli isolates.
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The prevalence of ESBLs among clinical isolates, espe-
cially E. coli and K. pneumoniae, has increased signifi-
cantly over the past two decades [3]. Despite this
increase in ESBLs worldwide, there is a paucity of local
reports on the prevalence of ESBL-EC [14-16]. Bindayna
et al. [17] reported a high level of blaCTX-M-positive
ESBL-EC; however, they did not determine the type of
CTX-M enzymes present. This study is the first in Saudi
Arabia to specifically determine the CTX-M-types of
ESBLs, to determine strain typing and to determine thespread of the ST131 clone among ESBL-EC isolates sam-
pled from inpatients.
A total of 152 E. coli clinical isolates collected from a
hospitalised patient population over a 10-month time
period from September 2010 to June 2011 were evalu-
ated for the production of ESBL enzymes. The results
revealed that 31 (20.4%) of 152 E. coli isolates produced
ESBL. This study demonstrated an increasing prevalence
of ESBL-EC. In previous local studies, the prevalence
rates of ESBL-EC were 6.5% and 10.3% in 2002 and
2004, respectively [14], and the prevalence rates were
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ively [15]. Recently, the prevalence of ESBL-EC in uro-
pathogenic E. coli was 33.3% [16].
Currently, CTX-M enzymes are replacing SHV and
TEM enzymes as the prevalent ESBL type [2]. In this
study, all ESBL-EC produced the ESBL CTX-M con-
comitant with the narrow-spectrum β-lactamase TEM-1.
None of the isolates produced SHV β-lactamase. From
our study, we documented that CTX-M enzymes are the
dominant ESBLs in Saudi Arabia. CTX-M-15-producing
E. coli have spread worldwide [1]. Our results revealed
that CTX-M-type enzymes accounted for 100% of all
ESBLs. These results reflect the global trend toward a
pandemic spread of CTX-M-type ESBLs in E. coli. While
the CTX-M-1 group was predominant, the CTX-M-9
group was rarely reported in Saudi Arabia: within the
CTX-M family, CTX-M-1- and CTX-M-9-like genes had
prevalence rates of 96.77% and 3.23%, respectively. DNA
sequencing revealed that CTX-M-15 is the sole enzyme
with a CTX-M-1-like gene, while CTX-M-27, a variant
of CTX-M-14, is the sole enzyme with a CTX-M-9-like
gene. This is the first study to describe CTX-M-15 and
CTX-M-27 enzymes among ESBL-EC isolates in Saudi
Arabia and to document a high prevalence of CTX-M-
15. In previous local studies, two groups of enzymes;
CTX-M-1- and CTXM-9-like genes, were identified in
CTX-M-positive K. pneumoniae isolates, with prevalence
rates of 60% and 40%, respectively [10]. CTX-M-15 and
CTX-M-27 enzymes hydrolyse cefotaxime and ceftazi-
dime. CTX-M-27 confers stronger resistance to ceftazi-
dime than CTX-M-14 [23]. Strikingly, we identified one
ESBL-EC isolate producing CTX-M-27 in Saudi Arabia
for the first time.
E. coli ST131 is a worldwide pandemic clone that
causes antimicrobial-resistant infections. The pandemic
spread of CTX-M-15 ESBL-EC was identified in 2008 on
three continents [7,24]. Since then, the worldwide preva-
lence of ST131 harbouring a broad range of virulence
and resistance genes on a transferable plasmid has been
confirmed [7]. E. coli ST131 can harbour a variety of β-
lactamase genes; most often, these include CTX-M, and,
less frequently, TEM, SHV, and CMY. The E. coli ST131
clone has been reported worldwide; this clone is fre-
quently multidrug-resistant, commonly carries CTX-M-
15 [6,8]. CTX-M-15-producing E. coli ST131 has not yet
been reported in Saudi Arabia. A particularly interesting
result of this study is the finding that ST131 was preva-
lent among blaCTX-M-15-positive E. coli isolates (20/30;
66.66%) in Saudi Arabia. However, the CTX-M-27-posi-
tive isolates were not ST131. Our results suggested that
ST131-CTX-M-15-ESBL-EC strains have circulated in
Saudi Arabia. A high prevalence of the clone (∼30%–60%)
has been identified amongst fluoroquinolone-resistant E.
coli. ST131 comprised 64% of community-acquired and84% of hospital-acquired cefpodoxime-resistant E. coli in-
fections [25]. ST131 comprised 53% and 30% of CTX-M
ESBL-producing E. coli in Chicago and Pittsburgh, re-
spectively [26,27]. In Indonesia, 36.8% of CTX-M-15-posi-
tive E. coli belonged to the O25b-ST131 lineage [28]. A
high prevalence of the CTX-M-15-producing O25b-
ST131 E. coli clone in Bulgaria has been reported [29], as
have high proportions of ESBL-producing E. coli ST131
isolates from India, Pakistan, Iran, and Lebanon [30]. In
early studies, ST131 clones producing CTX-M-15 had the
propensity to cause community-onset infections, espe-
cially urinary tract infections [30-32]. However, this clone
has also been recently identified in isolates recovered from
health care settings, such as hospitals and nursing homes
[33,34]. There was a high proportion of ST131 among
CTX-M-15 producing isolates.
Limitations of this study include that it was performed
at a single institution in Saudi Arabia and that a low
number of isolates were studied. Furthermore, this study
was conducted on hospitalised patients, which does not
reflect the epidemiological changes in the Saudi commu-
nity. Thus, the study results may not reflect the epidemi-
ology of different geographic areas within the kingdom.
Despite these limitations, to our knowledge, this is the
first study describing the genetic characteristics of
ESBL-EC in Saudi Arabia. This study demonstrates a
much higher overall prevalence of ESBL-EC than has been
previously reported in Saudi Arabia, with CTX-M-type
enzymes being the predominant ESBLs. In addition, the
study results provide evidence for the dominance of CTX-
M-15-producing isolates in Saudi Arabia [9,10,12,13,17]
and that the predominance of ST131 is likely responsible
for the clonal expansion of ESBL-EC in Saudi Arabia, con-
clusions that are consistent with the changing epidemi-
ology of ESBL-EC worldwide.
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